Washington Trust Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Washington Trust Advisors's VRTX Position: Q2 2026 in Review
Washington Trust Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q2 2026, selling an estimated $2.22K and leaving 372 shares worth $185K. The position accounts for 0.01% of the portfolio, ranked #237.
Washington Trust Advisors first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $790K in Q1 2022. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Washington Trust Advisors held 372 shares of Vertex Pharmaceuticals worth $185K as of Q2 2026.
- Washington Trust Advisors sold 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
- Vertex Pharmaceuticals made up 0.01% of Washington Trust Advisors's portfolio in Q2 2026, its #237 holding.
- Washington Trust Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
- Washington Trust Advisors's Vertex Pharmaceuticals position peaked at $790K in Q1 2022.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.